$46.5+ Billion Gene Therapy Market to Grow at 22.8% CAGR, Globally, by 2030 | Harnessing the Power of Gene Editing
The increasing number of approvals of gene therapies within North America and Europe are the major reasons for market growth.
PORTLAND, OREGON, UNITED STATES, March 13, 2024 /EINPresswire.com/ -- ๐๐ง๐๐ซ๐๐๐ฌ๐ ๐ข๐ง ๐ญ๐ก๐ ๐ฉ๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐ ๐จ๐ ๐๐ก๐ซ๐จ๐ง๐ข๐ ๐๐ข๐ฌ๐จ๐ซ๐๐๐ซ๐ฌ, ๐ซ๐ข๐ฌ๐ ๐ข๐ง ๐ ๐จ๐ฏ๐๐ซ๐ง๐ฆ๐๐ง๐ญ ๐ฌ๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ, ๐๐ง๐ ๐๐ญ๐ก๐ข๐๐๐ฅ ๐๐๐๐๐ฉ๐ญ๐๐ง๐๐ ๐จ๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐๐๐ง๐๐๐ซ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ซ๐ข๐ฏ๐ ๐ญ๐ก๐ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก ๐จ๐ ๐ญ๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐๐ซ๐ค๐๐ญ. ๐๐ง ๐ญ๐ก๐ ๐จ๐ญ๐ก๐๐ซ ๐ก๐๐ง๐, ๐ก๐ข๐ ๐ก ๐๐จ๐ฌ๐ญ ๐จ๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ข๐๐ฌ ๐ซ๐๐ฌ๐ญ๐ซ๐๐ข๐ง๐ฌ ๐ญ๐ก๐ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก ๐ญ๐จ ๐ฌ๐จ๐ฆ๐ ๐๐ฑ๐ญ๐๐ง๐ญ. ๐๐จ๐ฐ๐๐ฏ๐๐ซ, ๐ญ๐ก๐ ๐ฉ๐ซ๐๐ฌ๐๐ง๐๐ ๐จ๐ ๐๐๐ฏ๐๐ง๐๐๐ ๐ก๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐ข๐ง๐๐ซ๐๐ฌ๐ญ๐ซ๐ฎ๐๐ญ๐ฎ๐ซ๐ ๐ข๐ฌ ๐๐ง๐ญ๐ข๐๐ข๐ฉ๐๐ญ๐๐ ๐ญ๐จ ๐ฉ๐๐ฏ๐ ๐ญ๐ก๐ ๐ฐ๐๐ฒ ๐๐จ๐ซ ๐ฅ๐ฎ๐๐ซ๐๐ญ๐ข๐ฏ๐ ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ.
Allied Market Research published a report, titled, โGene Therapy Market by Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others), by Application (Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2020-2030.โ According to the report, the global Gene Therapy Market Size was Valued at USD 6.0 billion in 2020 and is Projected to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% from 2021 to 2030.
The gene therapy market refers to the pharmaceutical and biotechnology industry segment focused on the development, production, and commercialization of gene therapy products and treatments. Gene therapy involves the introduction, removal, or modification of genetic material within an individual's cells to treat or prevent diseases.
๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/2841
๐๐๐ซ๐'๐ฌ ๐ ๐๐ซ๐๐๐ค๐๐จ๐ฐ๐ง ๐จ๐ ๐ค๐๐ฒ ๐๐ฌ๐ฉ๐๐๐ญ๐ฌ ๐จ๐ ๐ญ๐ก๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐๐ซ๐ค๐๐ญ:
๐ฐTechnology and Approaches: Gene therapy employs various technologies and approaches to target genetic abnormalities underlying diseases. This includes gene addition (introducing a functional gene into cells), gene editing (modifying existing genes within cells), and gene silencing (suppressing the expression of disease-causing genes). Technologies such as CRISPR-Cas9, viral vectors (e.g., adenoviruses, lentiviruses), and non-viral vectors are commonly used in gene therapy research and development.
๐ฐTherapeutic Areas: Gene therapy holds promise for treating a wide range of diseases, including genetic disorders (e.g., cystic fibrosis, muscular dystrophy), rare diseases, cancer, cardiovascular diseases, neurological disorders, and infectious diseases. Advances in gene therapy research have expanded its potential applications across diverse therapeutic areas.
๐ฐMarket Growth Drivers: The gene therapy market has witnessed significant growth in recent years, driven by factors such as advancements in gene editing technologies, increasing investment in research and development, growing understanding of the genetic basis of diseases, and regulatory approvals for gene therapy products. Additionally, the emergence of personalized medicine and precision therapies has spurred interest in gene therapy approaches tailored to individual patients.
๐ฐClinical Successes and Challenges: Several gene therapy products have demonstrated clinical success and received regulatory approval in recent years, including treatments for spinal muscular atrophy, inherited retinal diseases, and certain types of cancer. However, the field also faces challenges such as safety concerns, immune responses to viral vectors, manufacturing complexities, and high treatment costs. Overcoming these challenges is crucial for the continued growth and adoption of gene therapy treatments.
๐ฐRegulatory Environment: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a key role in overseeing the development and approval of gene therapy products. Regulatory pathways for gene therapy products may differ from those of traditional pharmaceuticals due to the unique nature of gene-based treatments, requiring innovative approaches to safety and efficacy assessment.
๐ฐMarket Landscape and Players: The gene therapy market encompasses a diverse array of stakeholders, including pharmaceutical companies, biotechnology firms, academic research institutions, contract manufacturing organizations (CMOs), and regulatory bodies. Market players may collaborate on research partnerships, licensing agreements, and commercialization efforts to advance gene therapy development and bring innovative treatments to market.
๐๐จ๐ฉ ๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ:
โข Gilead Sciences
โข Orchard Therapeutics.
โข Bristol-Myers Squibb.
โข Therapeutics plc
โข Adverum Biotechnologies, Inc.
โข Amgen Inc.
โข Jazz Pharmaceuticals,
โข Shenzhen SiBiono Genentech
โข Adaptimmune
โข Novartis AG
โข Shanghai Sunway Biotech Co., Ltd.
๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง ๐๐๐ง ๐๐ ๐๐จ๐ง๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ฌ๐๐ฏ๐๐ซ๐๐ฅ ๐๐๐๐ญ๐จ๐ซ๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ :
On the basis of gene type, the antigen segment accounted for the highest market share in 2020, generating nearly one-fourth of the global gene therapy market. Rise in the prevalence of diseases such as autoimmune diseases & cancer and increase in R&D activities associated with antigen-based gene therapies propel the growth of the segment. The deficiency segment, however, is anticipated to cite the fastest CAGR of 26.0% from 2021 to 2030.
On the basis of application, the oncological disorders segment generated the highest share in 2020, holding more than two-fifths of the global gene therapy market. The same segment is also expected to cite the fastest CAGR of 23.5% from 2021 to 2030. Increase in the prevalence of cancer and availability of diverse gene therapy products that can be used to treat cancer fuel the segment growth.
On the basis of region, North America contributed to the major market share in terms of revenue 2020, holding nearly half of the global gene therapy market. The Asia-Pacific region, simultaneously, is projected to cite the fastest CAGR of 25.4% from 2021 to 2030. This is attributed to the facts such as rise in the prevalence of chronic diseases, increase in healthcare expenditure, developments in healthcare infrastructure, availability of reimbursements, and the presence of major market players in the province.
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/purchase-enquiry/2841
๐๐ฎ๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐๐ฌ ๐๐จ๐ฎ ๐๐ง๐ฌ๐ฐ๐๐ซ ๐ญ๐จ ๐๐๐ฅ๐จ๐ฐ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง:
โข Which are the driving factors responsible for the growth of market?
โข Which are the roadblock factors of this market?
โข What are the new opportunities, by which market will grow in coming years?
โข What are the trends of this market?
โข Which are main factors responsible for new product launch?
โข How big is the global & regional market in terms of revenue, sales and production?
โข How far will the market grow in forecast period in terms of revenue, sales and production?
โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
โข Which region has more opportunities?
By Region Outlook
โข North America
(U.S., Canada, Mexico)
โข Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
โข Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
โข LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐ฌ:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฌ
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
